Skip to main content
. 2023 Dec 23;18:221–231. doi: 10.1016/j.xjon.2023.12.007

Table 2.

Pathologic nodal status by receipt of neoadjuvant therapy

Pathologic nodal status Patients, n (%)
Received neoadjuvant therapy 135 (64.29)
 ypN0 78 (58.0)
 ypN1 13 (9.8)
 ypN2 23 (16.8)
 ypN3 1 (0.7)
 ypNx/Unknown 21 (14.7)
Did not receive neoadjuvant therapy 75 (35.71)
 pN0 24 (34.6)
 pN1 6 (7.7)
 pN2 27 (34.6)
 pN3 0 (0)
 Unknown 18 (23.1)

Median survival and 5-year survival are reported for entire resection cohort, by neoadjuvant treatment status, and by lymph node status.